Adicet Bio, Inc. (ACET)

11.75 +1.49 (+14.52%) At close: 04:00PM EDT

Adicet Bio, Inc.

200 Clarendon Street
6th Floor
Boston, MA 02116
United States
650 503 9095
https://www.adicetbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 86

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA	CEO, Pres & Director	866.77k	N/A	1972
Dr. Aya Jakobovits Ph.D.	Founder & Independent Director	43.51k	N/A	1953
Mr. Brian Nicholas Harvey	Chief Financial Officer	596.79k	N/A	1961
Dr. Francesco Galimi M.D., Ph.D.	Chief Medical Officer & Sr. VP	651.39k	N/A	1968
Dr. Donald Healey	Chief Technology Officer	N/A	N/A	1962
Dr. Blake Aftab Ph.D.	Sr. VP & Chief Scientific Officer	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Corporate Governance

Adicet Bio, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.